Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board

Company to Initiate Investigational Cardiovascular Study with Dr. Azimi and NanoStilbene

Read More

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers


Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene

Read More

Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board


Dr. James Veltmeyer to Assist Company in Expansion of Clinical Applications of Pterostilbene Based Therapeutics

Read More

TSOI Subsidiary, SandBox Dental Labs, files 510(k) with FDA


Company Seeks Market Clearance for Oral Appliance To Treat Moderate Obstructive Sleep Apnea

Read More

TSOI Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.


Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

TSOI files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity


Company Developing Proprietary Products that Help Immune System Fight Cancer

Read More

TSOI Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.


Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

TSOI files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof


Company Developing Proprietary Products that Help Immune System Fight Cancer

Read More

TSOI Announces Exclusive Patent License Agreement to innaMune with its Subsidiary Emvolio, Inc.


Company Developing Proprietary Products that Help Immune System Fight Cancer

Read More

TSOI files Patent on Blood Derived Innate Immune System Stimulator


Company Resurrecting “Transfer Factor” Immunotherapeutic for Treatment of Cancer

Read More

TSOI Announces Exclusive Patent License Agreement with its Subsidiary Emvolio, Inc.


Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

SandBox Dental Labs, Inc. – is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.

Emvolio, Inc. – is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed.  The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Nutraceutical Division – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.